Beijing Yuanda Jiuhua Pharmaceutical

Beijing Grand Jiuhua Pharmaceutical is a core subsidiary of China Grand Pharmaceutical and Healthcare Holdings, specializing in the research, development, and manufacturing of respiratory and anti-infective medications. The company operates a high-tech production base in Beijing focused on inhalation formulations, including metered-dose inhalers (MDI) and dry powder inhalers (DPI). Its product portfolio primarily targets chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), featuring key products like Enure (mometasone furoate) and various combination therapies. Grand Jiuhua is recognized as a national high-tech enterprise and plays a significant role in the domestic Chinese market for respiratory drug delivery systems.